Roche Holding Ltd. Share Price Swiss Exchange
Stocks
CH0012032048
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Swiss Exchange
|
||
| - CHF | - |
|
| 09-03 | Hutchmed Enters Licensing Agreement With GSK for Cancer Drug | DJ |
| 09-02 | Roche, Treeline Biosciences to Evaluate Combination Therapy for B-cell Lymphomas | MT |
| Market Cap | 285B 352B 303B 261B 487B 33,261B 489B 3,370B 1,308B 17,065B 1,323B 1,294B 54,977B | P/E 2026 * |
19.9x | P/E 2027 * | 17.6x |
|---|---|---|---|---|---|
| Enterprise Value | 296B 366B 315B 270B 506B 34,529B 507B 3,499B 1,358B 17,716B 1,373B 1,343B 57,071B | EV / Sales 2026 * |
4.73x | EV / Sales 2027 * | 4.42x |
| Free-Float |
88.78% | Yield 2026 * |
2.8% | Yield 2027 * | 2.86% |
Last Transcript : Roche Holding Ltd.
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 14/03/2023 | |
Alan Hippe
DFI | Director of Finance/CFO | 59 | 05/06/2011 |
| Chief Operating Officer | - | 30/09/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
André Hoffmann
BRD | Director/Board Member | 68 | 31/12/1995 |
Severin Schwan
CHM | Chairman | 59 | 14/03/2023 |
| Director/Board Member | 73 | 02/03/2015 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.88% | -2.15% | +58.05% | +105.91% | 1,024B | |
| -1.15% | +2.68% | +54.25% | +71.29% | 663B | |
| -1.44% | +0.38% | +20.65% | +75.54% | 453B | |
| +0.14% | -0.47% | +30.20% | +40.61% | 352B | |
| -1.33% | +4.72% | +24.62% | +47.60% | 304B | |
| -1.15% | +0.30% | -0.69% | +11.83% | 252B | |
| -1.55% | +1.11% | +54.15% | +72.13% | 236B | |
| -0.88% | +1.15% | -14.60% | -54.84% | 206B | |
| -0.15% | +3.65% | +31.24% | +100.90% | 187B | |
| Average | -0.93% | +1.09% | +28.65% | +52.33% | 408.71B | |
| Weighted average by Cap. | -0.96% | +0.55% | +37.63% | +67.00% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 62.61B 77.34B 66.55B 57.2B 107B 7,302B 107B 740B 287B 3,746B 290B 284B 12,069B | 65.43B 80.82B 69.54B 59.77B 112B 7,630B 112B 773B 300B 3,915B 303B 297B 12,612B |
| Net income | 14.5B 17.91B 15.41B 13.24B 24.77B 1,691B 24.84B 171B 66.47B 867B 67.24B 65.77B 2,794B | 16.32B 20.15B 17.34B 14.91B 27.88B 1,903B 27.96B 193B 74.82B 976B 75.68B 74.03B 3,145B |
| Net Debt | 10.87B 13.42B 11.55B 9.93B 18.57B 1,267B 18.62B 128B 49.83B 650B 50.4B 49.3B 2,095B | 4.02B 4.96B 4.27B 3.67B 6.87B 469B 6.89B 47.5B 18.43B 241B 18.64B 18.24B 775B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
